10 
■Part IV of the NIH Guidelines sh^dl be eliminated, with the 
followinq exceptions: 
"(a) Ttiose definitions listed in Part IV-C which may be needed 
to clarify statements nade elsewhere in the Guidelines shall 
be retained. 
■(b) Those portions of Part IV-E defining the oorrposition of RAC 
and prescribing rules for RAC procedures shall be retained. 
■(c) The following statement shall be added: 
■Each institution conducting or sponsoring recombinant CNA 
research should taJce responsibility for monitoring its own 
activities in this area. Any unusual events that might be 
associated with the use of recombinant DNA molecules should 
be reported to the Director, NIH." 
7. Accept the fifth section of the B^Lltimore-Ca^^3bell proposed with deletion 
of the words "submitted in support of requests for exceptions from the 
prohibitions," as follows: 
"Section VI of the Guidelines will be eliminated, except for those 
portions of Section VI-F relevant to the protection of pre^rietary 
information. " 
Dr. Bems seconded the motion. 
Dr. Saginc^ suggested an amendment to Dr. Harris' motion in the form of a 
policy statement that there is a continuing need for the RAC and applicable 
reoombinant CNA guidelines. The purpose of the amendment was to indicate 
that the Adelberg-Zinder proposal is not being accepted. Dr. Harris agreed 
to the amendment. 
Ms. King said she wanted the RAC to vote on replacing parts 1 and 6 of the 
Baltimore motion with wording from the Wor)cing Group proposal. It was sug- 
gested that votes be on one part at a time. Ms. King then moved to replace 
the first part of Dr. Baltimore's motion with the first section of the Working 
Group's proposal as follows: 
"Section I-A of the Guidelines would be amended to read as follows: 
"I-A. Purpose . The purpose of these Guidelines is to specify 
standard practices for constructing and handling (i) reoombinant 
CNA molec^es and (ii) organisms and viruses containing reoombin£mt 
DNA molecules." 
[2011 
